Abstract
Many AD target combinations are being explored for multi-target drug design.
New databases and models increase the potential of computational drug design
Liraglutide and other antidiabetics are strong candidates for repurposing to AD.
Donecopride a dual 5-HT/AChE inhibitor shows promise in pre-clinical studies
Alzheimer's Disease is a complex and multifactorial disease for which the mechanism is still not fully understood. As new insights into disease progression are discovered, new drugs must be designed to target those aspects of the disease that cause neuronal damage rather than just the symptoms currently addressed by single target drugs. It is becoming possible to target several aspects of the disease pathology at once using multi-target drugs (MTDs). Intended as an introduction for non-experts, this review describes the key MTD design approaches, namely structure-based, in silico, and data-mining, to evaluate what is preventing compounds progressing through the clinic to the market. Repurposing current drugs using their off-target effects reduces the cost of development, time to launch, and the uncertainty associated with safety and pharmacokinetics. The most promising drugs currently being investigated for repurposing to Alzheimer's Disease are rasagiline, originally developed for the treatment of Parkinson's Disease, and liraglutide, an antidiabetic. Rational drug design can combine pharmacophores of multiple drugs, systematically change functional groups, and rank them by virtual screening. Hits confirmed experimentally are rationally modified to generate an effective multi-potent lead compound. Examples from this approach are ASS234 with properties similar to rasagiline, and donecopride, a hybrid of an acetylcholinesterase inhibitor and a 5-HT4 receptor agonist with pro-cognitive effects. Exploiting these interdisciplinary approaches, public-private collaborative lead factories promise faster delivery of new drugs to the clinic.
Introduction
Current therapies available for the treatment of Alzheimer's Disease (AD) show limited ability to modify the disease. To date the focus for AD has been on the depletion of acetylcholine, but AD is a complex multifactorial disease with diverse clinical symptoms. AD causes the gradual onset of multiple cognitive deficits, affecting language, episodic memory and attention (Karran et al., ). The disease pathology includes extracellular amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles, inflammation, oxidative stress, iron dysregulation and ultimately neuronal cell death (Carreiras et al., ). It is accepted that multifactorial diseases require the simultaneous modulation of multiple targets to manage the course of disease progression (Cavalli et al., ), leading to growth in multi-target drug (MTD) design (Hopkins, ). This review focuses on possible targets, their combinations, and the three main approaches to designing MTDs: structure-based design, data mining/repurposing, and in silico screening. The application of rational drug design to MTDs is difficult but with the recent advances in experimental and computational approaches, a combined approach harnessing the best attributes of each method should ultimately deliver success in the future.
Targets and current therapies; limitations in alzheimer's disease
The multifactorial nature of AD means there are many possible therapeutic targets. Current monotherapeutic treatments focus mainly on acetylcholinesterase (AChE) inhibition due to the early cholinergic hypothesis that cognitive dysfunctions of AD may be attributed to decreased neurotransmission at cholinergic synapses as a result of neuronal cell death (Bartus et al., ). AChE therapies provide symptomatic relief, but fail to reverse disease progression (Wilkinson et al., ; Deardorff et al., ), although recent work suggests that donepezil (Table 1) may enhance Aβ clearance (Mohamed et al., ). The amyloid hypothesis that the generation of toxic Aβ from amyloid precursor protein (APP) and Aβ aggregation result in the pathophysiological changes associated with AD (Figure 1) led to compounds targeting Aβ (Karran et al., ; Eisele et al., ). Although small molecules can target Aβ aggregation (see Table 1), the main strategy is immunotherapy, still in clinical trials (Palmer, ; Wisniewski and Goñi, ). Better understanding of protein aggregation is now available to guide therapeutic intervention on both Aβ and tau aggregation (Eisele et al., ).
Table 1
| Targets | Drug name | Structure | Comment |
|---|---|---|---|
| (A) APPROVED DRUGS | |||
| Acetylcholinesterase | Donepezil |  | Approved drug |
| Rivastigmine |  | Approved drug | |
| Galantamine |  | Approved drug | |
| Tacrine |  | Withdrawn | |
| Monoamine oxidase | Rasagiline |  | Approved for PD Phase II for AD |
| Targets | Parent compounds | Compound | References |
| (B) MULTI-TARGET DESIGNED LIGANDS | |||
| Cholinesterase Aβ aggregation | Oxoisoaporphine Tacrine |  | Tang et al., |
| Cholinesterase Aβ aggregation | Donepezil |  | Ozer et al., |
| AChE BACE-1 | Huprine Tacrine |  | Galdeano et al., |
| Cholinesterase MAO Aβ aggregation | Donepezil Compound 28 (Pérez et al., ) |  | Samadi et al., |
| Cholinesterase MAO | Donepezil Compound 28 |  | Bolea et al., |
| MAO Cholinesterase | Donepezil PF9601N |  | Bautista-Aguilera et al., |
| MAO Cholinesterase | Tacrine Selegiline (deprenyl) |  | Lu et al., |
| Cholinesterase Reactive oxygen species | Memoquin Lipoic acid |  | Rosini et al., |
| MAO Metal chelator Aβ aggregation Cholinesterase | Resveratrol |  | Lu et al., |
| Metal chelator Aβ aggregation | Resveratrol Clioquinol |  | Li et al., |
Targets, drugs, and new multi-target ligands to combat Alzheimer's Disease (AD).
Figure 1
Following on from direct targeting of Aβ, a relatively new target in AD is the β-secretase (BACE-1) enzyme. Inhibition of this protease BACE-1 should reduce the levels of Aβ in the brain (Vassar, ). BACE-1 inhibitors in clinical trials include AZD3293 in phase II/III (NCT02245737) and MK8931 (verubecestat) in phase III (NCT01953601). While these drugs show promise, there are potential complications from a possible role in synaptic function (Kandalepas and Vassar, ) and increased memory impairment and seizures in BACE-1 –/– mice (Hu et al., ).
Another major enzyme target, monoamine oxidase (MAO) is inhibited in Parkinson's Disease (PD) to spare the neurotransmitters depleted by neuronal death. The PD drug, rasagiline (see below), is a MAO-B inhibitor in clinical trials for AD (Weinreb et al., ).
N-methyl-D-aspartate (NMDA) is a glutamate receptor and is the only other target besides AChE for which a therapy has been approved (Anand et al., ). NMDA receptors are over-stimulated in AD brains due to excessive release of glutamate from neurons. This causes high levels of calcium ion influx and activation of enzymes that can cause neuronal cell death (Zheng et al., ). NMDA receptors have also been linked to tau hyper-phosphorylation and Aβ toxicity (Couratier et al., ). Memantine is the only approved NMDA receptor antagonist for the treatment of moderate to severe AD (Lipton, ).
Other receptors being explored are the 5-hydroxytryptamine (5-HT) serotonin receptors, in particular subtype 4 (5-HT4R) that is involved in mood, memory, and learning. 5-HT4R has been linked to memory deficits such as those seen in AD (Cho and Hu, ; Lezoualc'h, ; Russo et al., ). Stimulation causes release of ACh and increases other neurotransmitters (Licht et al., ).
Inhibition of these targets individually with current drugs (Table 1) has been ineffective at reversing the progression of the disease. A possible answer lies in a polypharmacological approach to modify activities of several of these targets simultaneously, particularly those associated with the progression of the disease. MTDs developed for AD have modified two or more of known targets (cholinesterases, MAOs, acetylcholine receptors, serotonin receptors) or have properties thought to retard disease progression, such as metal chelation, antioxidant or anti-inflammatory activity, or prevention of Aβ or tau aggregation. Ligands for combinations of drug targets should be evaluated against disease progression to define optimal target combinations.
Datamining and repurposing
Repurposing is the development of existing or abandoned drugs for new indications (Boguski et al., ), related to the original purpose or after off-target effects are identified by datamining. Repurposing reduces the time to launch, cost of development, and the uncertainty associated with safety and pharmacokinetics (Kim, ).
Datamining is a way of using pre-existing knowledge about molecules and applying it to develop new drugs (Sirota et al., ; Corbett et al., , ). For example, clinical data can be used to identify unanticipated benefits in side effects seen in clinical trials, allowing the early repurposing of therapies (Loging et al., ). The most promising drug currently being investigated for repurposing is rasagiline, a selective, irreversible MAO-B inhibitor for the treatment of PD (Youdim et al., , ). The repurposing to AD stems from the ability of rasagiline to regulate the non-amyloidogenic processing of APP (Yogev-Falach et al., ; Bar-Am et al., ). Rasagiline also shows neuroprotective activity due to the propargylamine moiety that activates Bcl-2 and down-regulates the Bax proteins (Youdim et al., ). It is now in Phase II trial for the treatment of AD (www.clinicaltrials.gov/ct2/show/NCT02359552).
Natural products provide another potential source of MTDs (Ji et al., ; Prati et al., ). Datamining could harness their potential and then synthetic analogs and derivatives created to enhance their activity (Agis-Torres et al., ). Huperzine A, a dietary supplement in China, is an AChE inhibitor (Xing et al., ) seemingly with beneficial effects on cognitive function and daily living in AD patients, but the clinical trials to date have poor methodological approaches and so results are inconclusive (Xu et al., ; Rafii et al., ). Synthetic derivatives like huprine X and huprine-tacrine hybrids have been developed to improve on the potency and efficacy of huperzine A (Galdeano et al., ).
One promising repurposing area is from diabetes to AD, first considered because type 2 diabetes is a risk factor for AD (Schrijvers et al., ). Insulin signaling is impaired in the brains of Alzheimer's patients (Moloney et al., ) so several aspects of insulin signaling and regulation have been targeted. For example, Phase II clinical trials of intranasal insulin administration showed improved biomarkers for early AD including amyloid and tau indicators in cerebrospinal fluid (CSF) (Craft et al., ). Long-lasting glucagon-like peptide 1 (GLP-1) analogs that promote the secretion of insulin are also in clinical trials. Three GLP-1 analogs with potential therapeutic value in AD (Corbett et al., ; Hölscher, ), have shown in vivo benefits in mouse AD models (Gengler et al., ). Two of these are Exendin-4 in Phase II clinical trial (See www.clinicaltrials.gov/ct/show/NCT01255163) and Liraglutide, a GLP-1 receptor agonist. Liraglutide crosses the blood brain barrier (BBB) in animal models (Hunter and Hölscher, ). It decreases intracellular APP, Aβ, and Fe2+-related neurodegeneration, but also improves synaptic plasticity and cognitive function, reducing AD pathology (McClean et al., ; McClean and Hölscher, ).
Databases and open-access mining
The construction of AD knowledge bases will facilitate the repurposing of drugs and our understanding of the neurosignaling pathways involved. One such example is AlzPlatform, an AD domain-specific chemogenomics database allowing the identification of off-target effects and the repurposing of compounds (Liu et al., ). AlzPlatform contains the established computational algorithm TargetHunter, which is an in silico target identification tool for small molecules (Wang et al., ).
While there is a wealth of open access chemical information available to aid repurposing of FDA approved drugs, compound libraries held by pharmaceutical companies are, for the most part, unavailable. Datamining to find possible targets for these compounds could prove fruitful. An open-innovation drug-repositioning project between AstraZeneca and the Medical Research Council (http://www.labtalk.astrazeneca.com/hot-topics/open-innovation-in-drug-repositioning/) has started and the National Center for Advancing Translational Sciences (NCATS) has created a similar collaboration with 8 pharmaceutical companies. One of the compounds from this program is the Src tyrosine kinase inhibitor, AZD0530 (Saracatinib), being repurposed for the treatment of AD (Larson et al., ; Nygaard et al., ). The European Lead Factory (www.europeanleadfactory.eu) is another initiative set up to allow sharing of commercial compound libraries via collaborative public-private partnerships. The compound library, a pool of 30 partner libraries, provides a collection of over 500,000 compounds available for academic groups and pharmaceutical companies to screen experimentally against their chosen targets with great potential to generate new therapeutics.
Rational drug design
Rational drug design is a traditional method for drug development based on structure-function analysis. Successful rational drug design requires the logical and systematic changing of substituents to modify the properties of a compound to reach the desired effect. When applied to MTD design, it means combining pharmacophores of multiple drugs to give complex combinations, then compensating for any disadvantage to the individual targets.
M30, a brain-permeable iron chelator and brain selective MAO inhibitor, was designed on the rationale that MAO and iron are elevated in the brains of AD patients, and this leads to oxidative stress and neurodegeneration (Youdim, ). The MAO inhibition is due to the propargylamine of the FDA-approved anti-PD drug rasagiline (Youdim, ). The iron chelating activity comes from the prototype iron chelator VK28 (Zheng et al., ). M30 irreversibly inhibits both MAO-A and -B with IC50 values of 37 ± 2 nM and 57 ± 1 nM respectively, less selective than rasagiline (412 nM and 4.4 nM, respectively) (Zheng et al., ). It also regulates APP via its iron chelating ability since APP is a metalloprotein with an iron responsive element in the 5′ untranslated region (UTR) (Youdim, ). Therefore, it has a direct effect on Aβ levels.
To reduce the possibility of adverse effects of metal chelation in the periphery, a second-generation molecule and prodrug, M30D, was designed from tacrine, rivastigmine, and rasagiline (Zheng et al., ,, ). It was 3-fold more potent against MAO-A (IC50 of 7.7 nM) than the parental molecule, retaining the same MAO-B inhibition (Zheng et al., ). It is metabolized to the active chelator form M30 by AChE and inhibits AChE with an IC50 of 500 nM in rat brain homogenates. With these characteristics, M30D is the first site-directed metal chelator with the potential to treat AD.
A similar MTD is ASS234 composed from donepezil and the propargylamine PF9601N. It binds to all the AChE/BuChE and MAO A/B enzymes, shows antioxidant, neuroprotective and suitable permeability properties. In vivo, ASS234 restores scopolamine-induced cognitive impairment to the same extent as donepezil, is less toxic, and prevents β-amyloid aggregation in the cortex of AD transgenic mice (Bolea et al., ; del Pino et al., ).
Another promising structure-based MTD is donecopride. Donecopride is a structural hybrid of donepezil, an AChE inhibitor, and RS67333, a 5-HT4R agonist. RS67333 is a partial 5-HT4R agonist that exerts a procognitive effect via its ability to promote cleavage of APP. RS67333 is structurally similar to donepezil, so it was postulated that it might inhibit AChE. It was indeed a submicromolar AChE inhibitor (Lecoutey et al., ; Rochais et al., ). Derivatives of RS67333 were then synthesized to improve the AChE activity, from which MR31147 (donecopride) was selected for its remarkable multi-target activity in vitro, including an IC50 for AChE of 16 nM (Lecoutey et al., ). Donecopride crosses BBB, has a nontoxic profile, and exerts a procognitive effect in vivo (Lecoutey et al., ). It will be interesting to see how this promising molecule progresses since 5-HT4 targeted therapies have been less commonly explored for AD.
These examples show how methodical rational drug design and experimental screening can be used to generate promising MTD candidates for the treatment of AD.
In silico screening
Rational drug design is currently the approach of choice for MTD design but it is labor intensive, so there is a need for more in silico screening to reduce costs and accelerate progress. New computer-based approaches for in silico screening (Ekins et al., ; Wang et al., ), such as quantitative structure-activity relationships, molecular modeling approaches, machine learning, data mining, and data analysis tools, use in vitro data to generate predictive models. Such models are very useful in the discovery and optimization of novel ligands with enhanced affinity to a drug target, as well as for optimization of physicochemical and pharmacokinetic properties of the drug candidates. Several of these in silico methods will be evaluated here in the context of selected MTD examples.
Virtual ligand screening is an alternative to experimental high throughput screening (Ekins et al., ). It can be used to screen whole databases of molecules and rank them based on their probability of binding to a drug target. The highest-ranking molecules can then be taken through to an experimental stage to confirm the hits and determine the most promising leads. Virtual screening can be either ligand based, where a diverse set of ligands are analyzed to build up a pharmacophore to score the screen against, or it can be structure-based, where molecules are docked onto the target and scored based on their likely affinity for the target. Quantitative structure-activity relationships (QSAR) is a form of ligand-based virtual screening but it uses a series of logic-based rules describing the chemical properties and substructures linked to activity to screen a database of molecules (Ekins et al., ).
Recently a virtual ligand screen (Bautista-Aguilera et al., ) was used for lead optimization of two donepezil hybrid compounds shown previously to inhibit MAO-A, MAO-B, AChE, and BuChE (Bolea et al., ). The 3D-QSAR analysis was carried out both to explain the binding of these compounds to the active sites of the enzymes and to predict substitutions that would increase binding. The QSAR model was used to generate 19 new molecules with substitutions predicted to increase the activity against MAOs and ChEs. The predicted IC50 values suggested that N-[(5-benzyloxy-1-methyl-1-H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine (compound 2) would be the most potent inhibitor of all four enzymes with values in the nanomolar range for MAO-A, MAO-B, and AChE, while BuChE was predicted at 1.3 μM. The experimental results showed that only 7 of the 19 compounds were active against all four enzymes, which demonstrates how difficult it can be to get activity against four enzymes in one molecule. However, as predicted, compound 2 was the most potent against all four enzymes, confirming the quality of the 3D-pharmacophores. Thus, in silico screening can be used to modify a lead compound and generate effective multi-potent inhibitors (Bautista-Aguilera et al., ).
Another option, rather than start from a lead molecule, is to use pharmacophore models to screen existing compound databases with the aim of generating hits against multiple targets. This approach has been used to identify dual inhibitors of BACE-1 and AChE using a combination of virtual screening and molecular docking of compounds from three compound databases. The strategy adopted follows a sequential screening model where the databases were screened in parallel against the two targets sequentially before filters were applied to select for compounds with desirable properties. Finally, docking of the chosen compounds led to 8 compounds from the original 501,799 that fit all the given criteria (Tyagi et al., ).
Importantly, in silico screening allows the early filtering of compounds based on properties, such as BBB permeability, which can reduce late stage attrition. However, screening sequentially means that compounds that fall below the cut-off criteria in the first round are not screened against the second target. To avoid loss of potential candidates, screening against the targets in parallel is essential (Steindl et al., ).
Concluding remarks
Over the past decade, there has been a substantial research effort to design MTDs for the treatment of AD. This focus on MTDs is aided by the understanding that AD is a complex and multifactorial disease affecting many interlinked pathological pathways. The lack of efficacy seen with the single target approach is compelling evidence that we needed to rethink the paradigm of drug design to treat these multifactorial diseases. MTD design offers a promising avenue for the progression of AD therapeutic intervention and could ultimately lead to a drug with the ability to reverse disease progression.
While there are many targets for disease-modifying drugs, it remains to be seen which combinations will prove efficacious. It seems logical that in order to reverse disease progression, we must target those aspects of the disease that cause neuronal damage, such as Aβ and oxidative damage, rather than just targeting the breakdown enzymes to alleviate the deficiencies caused by cell death. Of course, targeting a combination of both would relieve symptoms and prevent further neuronal loss.
In terms of the approach to MTD design, an integrated approach using a combination of in silico and rational drug design should reduce the cost of high throughput screening and progress discovery more rapidly. The MTD approach is also being used to combat the development of resistance to antimicrobials. MBX-500 has been designed as a hybrid of two classes of antibiotics, fluoroquinolone and anilinouracil, for the treatment of Clostridium difficile infections (Butler et al., ). TD-1792, a cephalosporin-vancomycin hybrid, has passed a phase II clinical trial for gram-positive skin infections (Stryjewski et al., ). While MTD design is in its infancy in the world of antibiotics, there is evidence that it could prove promising here too (East and Silver, ; Oldfield and Feng, ).
Overall, MTD design is a promising approach to modern medicines for complex diseases. Whether drugs will come from repurposing, rational drug design, in silico screening, or a combination approach we cannot predict, but the race is on to develop the first approved MTD capable of reversing AD pathology.
Funding
The authors thank COST Action CM1103 for the productive collaborations that inspired this work and for open access funding.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Author contributions
REH reviewed the literature and wrote the draft. All authors contributed to the conception, interpretation, and critical revision of the work. All authors have approved the final version of this review of current literature.
Acknowledgments
The authors thank the participants in COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” for productive collaborations and COST for funding open access publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- AD
Alzheimer's Disease
- AChE
acetylcholinesterase
- Aβ
amyloid beta
- MAO
monoamine oxidase
- MTD
multi-target drug
- N-methyl-D-aspartate
(NMDA receptor
- GABA
gamma-aminobutyric acid
- 5-HT4R
serotonin (5-HT) receptor type 4
- Glucagon-like peptide 1
(GLP-1)
- BBB
blood brain barrier.
Abbreviations
References
1
Agis-TorresA.SölhuberM.FernandezM.Sanchez-MonteroJ. M. (2014). Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for alzheimer's disease. Curr. Neuropharmacol.12, 2–36. 10.2174/1570159X113116660047
2
AnandR.GillK. D.MahdiA. A. (2014). Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology76, 27–50. 10.1016/j.neuropharm.2013.07.004
3
Bar-AmO.Yogev-FalachM.AmitT.SagiY.YoudimM. B. H. (2004). Regulation of protein kinase C by the anti-parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem.89, 1119–1125. 10.1111/j.1471-4159.2004.02425.x
4
BartusR. T.DeanR. L.IIIBeerB.LippaA. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science217, 408–417. 10.1126/science.7046051
5
Bautista-AguileraO. M.EstebanG.BoleaI.NikolicK.AgbabaD.MoraledaI.et al. (2014a). Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem.75, 82–95. 10.1016/j.ejmech.2013.12.028
6
Bautista-AguileraO. M.SamadiA.ChiouaM.NikolicK.FilipicS.AgbabaD.et al. (2014b). N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4yl)propoxy)-1H- indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual. J. Med. Chem.57, 10455–10463. 10.1021/jm501501a
7
BoguskiM. S.MandlK. D.SukhatmeV. P. (2009). Repurposing with a difference. Science324, 1394–1395. 10.1126/science.1169920
8
BoleaI.GellaA.MonjasL.PerezC.Rodriguez-FrancoM. I.Marco-ContellesJ.et al. (2013). Multipotent, permeable drug ASS234 inhibits A beta aggregation, possesses antioxidant properties and protects from A beta-induced apoptosis in vitro. Curr. Alzheimer Res.10, 797–808. 10.2174/15672050113109990151
9
BoleaI.Juarez-JimenezJ.de los RiosC.ChiouaM.PouplanaR.Javier LuqueF.et al. (2011). Synthesis, biological evaluation, and molecular modeling of donepezil and N- (5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl -N-methylprop-2-yn-1-ami ne hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem.54, 8251–8270. 10.1021/jm200853t
10
ButlerM. M.ShinabargerD. L.CitronD. M.KellyC. P.DvoskinS.WrightG. E.et al. (2012). MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic clostridium difficile. Antimicrob. Agents Chemother.56, 4786–4792. 10.1128/AAC.00508-12
11
CarreirasM. C.MendesE.Jesus PerryM. J.FranciscoA. P.Marco-ContellesJ. (2013). The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem.13, 1745–1770. 10.2174/15680266113139990135
12
CavalliA.BolognesiM. L.MinariniA.RosiniM.TumiattiV.RecanatiniM.et al. (2008). Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem.51, 347–372. 10.1021/jm7009364
13
ChoS.HuY. (2007). Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol.203, 274–278. 10.1016/j.expneurol.2006.07.021
14
CorbettA.PickettJ.BurnsA.CorcoranJ.DunnettS. B.EdisonP.et al. (2012). Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov.11, 833–846. 10.1038/nrd3869
15
CorbettA.WilliamsG.BallardC. (2013). Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals6, 1304–1321. 10.3390/ph6101304
16
CouratierP.LesortM.SindouP.EsclaireF.YardinC.HugonJ. (1996). Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol. Chem. Neuropathol.27, 259–273. 10.1007/BF02815108
17
CraftS.BakerL. D.MontineT. J.MinoshimaS.WatsonG. S.ClaxtonA.et al. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment a pilot clinical trial. Arch. Neurol.69, 29–38. 10.1001/archneurol.2011.233
18
DeardorffW. J.FeenE.GrossbergG. T. (2015). The use of cholinesterase inhibitors across all stages of Alzheimer's disease. Drugs Aging32, 537–547. 10.1007/s40266-015-0273-x
19
del PinoJ.RamosE.Bautista-AguileraO. M.Marco-ContellesJ.RomeroA. (2014). Wnt signaling pathway, a potential target for Alzheimer's disease treatment, is activated by a novel multitarget compound ASS234. CNS Neurosci. Ther.20, 568–570. 10.1111/cns.12269
20
EastS. P.SilverL. L. (2013). Multitarget ligands in antibacterial research: progress and opportunities. Expert Opin. Drug Discov.8, 143–156. 10.1517/17460441.2013.743991
21
EiseleY. S.MonteiroC.FearnsC.EncaladaS. E.WisemanR. L.PowersE. T.et al. (2015). Targeting protein aggregation for the treatment of degenerative diseases. Nat. Rev. Drug Discov.14, 759–780. 10.1038/nrd4593
22
EkinsS.MestresJ.TestaB. (2007a). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol.152, 9–20. 10.1038/sj.bjp.0707305
23
EkinsS.MestresJ.TestaB. (2007b). In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol.152, 21–37. 10.1038/sj.bjp.0707306
24
GaldeanoC.ViaynaE.SolaI.FormosaX.CampsP.BadiaA.et al. (2012). Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and Prion diseases. J. Med. Chem.55, 661–669. 10.1021/jm200840c
25
GenglerS.McCleanP. L.McCurtinR.GaultV. A.HoelscherC. (2012). Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging33, 265–276. 10.1016/j.neurobiolaging.2010.02.014
26
HölscherC. (2014). Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol.221, T31–T41. 10.1530/JOE-13-0221
27
HopkinsA. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol.4, 682–690. 10.1038/nchembio.118
28
HuX.FanQ.HouH.YanR. (2016). Neurological dysfunctions associated with altered BACE1-dependent neuregulin-1 signaling. J. Neurochem.136, 234–249. 10.1111/jnc.13395
29
HunterK.HölscherC. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci.13:33. 10.1186/1471-2202-13-33
30
JiH.-F.LiX.-J.ZhangH.-Y. (2009). Natural products and drug discovery can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?EMBO Rep.10, 194–200. 10.1038/embor.2009.12
31
KandalepasP. C.VassarR. (2014). The normal and pathologic roles of the Alzheimer's beta-secretase, BACE1. Curr. Alzheimer Res.11, 441–449. 10.2174/1567205011666140604122059
32
KarranE.MerckenM.De StrooperB. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov.10, 698–U1600. 10.1038/nrd3505
33
KimT.-W. (2015). Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. Neurotherapeutics12, 132–142. 10.1007/s13311-014-0325-7
34
LarsonM.ShermanM. A.AmarF.NuvoloneM.SchneiderJ. A.BennettD. A.et al. (2012). The complex PrPc-Fyn couples human oligomeric A beta with pathological tau changes in Alzheimer's disease. J. Neurosci.32, 16857. 10.1523/JNEUROSCI.1858-12.2012
35
LecouteyC.HedouD.FreretT.GiannoniP.GavenF.SinceM.et al. (2014). Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proc. Natl. Acad. Sci. U.S.A.111, E3825–E3830. 10.1073/pnas.1410315111
36
Lezoualc'hF. (2007). 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp. Neurol.205, 325–329. 10.1016/j.expneurol.2007.02.001
37
LiS.-Y.WangX.-B.KongL.-Y. (2014). Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease. Eur. J. Med. Chem.71, 36–45. 10.1016/j.ejmech.2013.10.068
38
LichtC. L.KnudsenG. M.SharpT. (2010). Effects of the 5-HT4 receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. Neurosci. Lett.476, 58–61. 10.1016/j.neulet.2010.04.002
39
LiptonS. A. (2006). Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov.5, 160–170. 10.1038/nrd1958
40
LiuH.WangL.LvM.PeiR.LiP.PeiZ.et al. (2014). AlzPlatform: an Alzheimer's disease domain-specific chemogenornics knowledgebase for polypharmacology and target identification research. J. Chem. Inf. Model.54, 1050–1060. 10.1021/ci500004h
41
LogingW.Rodriguez-EstebanR.HillJ.FreemanT. B.MigliettaJ. (2011). Cheminformatic/bioinformatic analysis of large corporate databases: application to drug repurposing. Drug Discov. Today Ther. Strateg.8, 109–116. 10.1016/j.ddstr.2011.06.004
42
LuC.GuoY.YanJ.LuoZ.LuoH.-B.YanM.et al. (2013a). Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. J. Med. Chem.56, 5843–5859. 10.1021/jm400567s
43
LuC.ZhouQ.YanJ.DuZ.HuangL.LiX. (2013b). A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. Eur. J. Med. Chem.62, 745–753. 10.1016/j.ejmech.2013.01.039
44
McCleanP. L.HölscherC. (2014). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology76, 57–67. 10.1016/j.neuropharm.2013.08.005
45
McCleanP. L.ParthsarathyV.FaivreE.HölscherC. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci.31, 6587–6594. 10.1523/JNEUROSCI.0529-11.2011
46
MohamedL. A.QosaH.KaddoumiA. (2015). Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastignnine in rats. ACS Chem. Neurosci.6, 725–736. 10.1021/acschemneuro.5b00040
47
MoloneyA. M.GriffinR. J.TimmonsS.O'ConnorR.RavidR.O'NeillC. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging31, 224–243. 10.1016/j.neurobiolaging.2008.04.002
48
NygaardH. B.van DyckC. H.StrittmatterS. M. (2014). Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimers Res. Ther.6:810.1186/alzrt238
49
OldfieldE.FengX. (2014). Resistance-resistant antibiotics. Trends Pharmacol. Sci.35, 664–674. 10.1016/j.tips.2014.10.007
50
OzerE. O.TanO. U.OzadaliK.KucukkilincT.BalkanA.UcarG. (2013). Synthesis, molecular modeling and evaluation of novel N '-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and A beta aggregation. Bioorg. Med. Chem. Lett.23, 440–443. 10.1016/j.bmcl.2012.11.064
51
PalmerA. M. (2011). Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol. Sci.32, 141–147. 10.1016/j.tips.2010.12.007
52
PérezV.MarcoJ. L.Férnandez-AlvarezE.UnzetaM. (1999). Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol.127, 869–876. 10.1038/sj.bjp.0702600
53
PratiF.UliassiE.BolognesiM. L. (2014). Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases. MedChemComm5, 853–861. 10.1039/c4md00069b
54
RafiiM. S.WalshS.LittleJ. T.BehanK.ReynoldsB.WardC.et al. (2011). A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology76, 1389–1394. 10.1212/WNL.0b013e318216eb7b
55
RochaisC.LecouteyC.GavenF.GiannoniP.HamidoucheK.HedouD.et al. (2015). Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J. Med. Chem.58, 3172–3187. 10.1021/acs.jmedchem.5b00115
56
RosiniM.SimoniE.BartoliniM.TarozziA.MateraR.MilelliA.et al. (2011). Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur. J. Med. Chem.46, 5435–5442. 10.1016/j.ejmech.2011.09.001
57
RussoO.Cachard-ChastelM.RiviereC.GinerM.SoulierJ.-L.BerthouzeM.et al. (2009). Design, synthesis, and biological evaluation of new 5-HT(4) receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. J. Med. Chem.52, 2214–2225. 10.1021/jm801327q
58
SamadiA.de los RíosC.BoleaI.ChiouaM.IriepaI.MoraledaI.et al. (2012). Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem.52, 251–262. 10.1016/j.ejmech.2012.03.022
59
SchrijversE. M. C.WittemanJ. C. M.SijbrandsE. J. G.HofmanA.KoudstaalP. J.BretelerM. M. B. (2010). Insulin metabolism and the risk of Alzheimer disease the rotterdam study. Neurology75, 1982–1987. 10.1212/WNL.0b013e3181ffe4f6
60
SirotaM.DudleyJ. T.KimJ.ChiangA. P.MorganA. A.Sweet-CorderoA.et al. (2011). Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med.3:96ra77. 10.1126/scitranslmed.3001318
61
SteindlT. M.SchusterD.LaggnerC.LangerT. (2006). Parallel screening: A novel concept in pharmacophore modeling and virtual screening. J. Chem. Inf. Model.46, 2146–2157. 10.1021/ci6002043
62
StryjewskiM. E.PotgieterP. D.LiY.-P.BarriereS. L.ChurukianA.KingsleyJ.et al. (2012). TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother.56, 5476–5483. 10.1128/AAC.00712-12
63
TangH.ZhaoL.-Z.ZhaoH.-T.HuangS.-L.ZhongS.-M.QinJ.-K.et al. (2011). Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation inhibitors. Eur. J. Med. Chem.46, 4970–4979. 10.1016/j.ejmech.2011.08.002
64
TyagiA.GuptaS.PandeyA.MohanC. G. (2010). Alzheimer's disease multi-target directed inhibitor design using sequential virtual screening techniques. Curr. Res. Inf. Pharm. Sci.11, 29–32. Available online at: http://www.niper.ac.in/29_crips.pdf
65
VassarR. (2014). BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimer's Res. Ther.6, 89–89. 10.1186/s13195-014-0089-7
66
WangL.MaC.WipfP.LiuH.SuW.XieX.-Q. (2013). Target hunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. Aaps J.15, 395–406. 10.1208/s12248-012-9449-z
67
WeinrebO.AmitT.Bar-AmO.YoudimM. B. H. (2010). Rasagiline: a novel anti-parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol.92, 330–344. 10.1016/j.pneurobio.2010.06.008
68
WilkinsonD. G.FrancisP. T.SchwamE.Payne-ParrishJ. (2004). Cholinesterase inhibitors used in the treatment of Alzheimer's disease the relationship between pharmacological effects and clinical efficacy. Drugs Aging21, 453–478. 10.2165/00002512-200421070-00004
69
WisniewskiT.GoñiF. (2014). Immunotherapy for Alzheimer's disease. Biochem. Pharmacol.88, 499–507. 10.1016/j.bcp.2013.12.020
70
XingS.-H.ZhuC.-X.ZhangR.AnL. (2014). Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evid. Based Complement. Alternat. Med.2014, 363985–363985. 10.1155/2014/363985
71
XuS. S.GaoZ. X.ZhengW.DuZ. M.XuW. A.YangJ. S.et al. (1995). Efficacy of tablet huperzine-a on memory, cognition, and behavior in Alzheimers-disease. Acta Pharmacol. Sin.16, 391–395.
72
Yogev-FalachM.AmitT.Bar-AmO.YoudimM. B. H. (2003). The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J.17, 2325. 10.1096/fj.03-0078fje
73
YoudimM. B. H. (2006). The path from anti Parkinson drug selegiline and rasagiline to multi-functional neuroprotective anti Alzheimer drugs ladostigil and M30. Curr. Alzheimer Res.3, 541–550. 10.2174/156720506779025288
74
YoudimM. B. H. (2013). Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp. Neurobiol.22, 1–10. 10.5607/en.2013.22.1.1
75
YoudimM. B. H.FinbergJ. P. M.LevyR.SterlingJ.LernerD.Berger-PaskinT.et al. (1995). R-Enantiomers of N-Propargyl-Aminoindan Compounds, their Preparation and Pharmaceutical Compositions Containing Them. U.S. Patent No: US5457133 A
76
YoudimM. B. H.GrossA.FinbergJ. P. M. (2001). Rasagiline N-propargyl-1R(+)-aminoindan, a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol.132, 500–506. 10.1038/sj.bjp.0703826
77
YoudimM. B. H.MaruyamaW.NaoiM. (2005). Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today41, 369–391. 10.1358/dot.2005.41.6.893613
78
ZhengH.FridkinM.YoudimM. (2014). From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals7, 113–135. 10.3390/ph7020113
79
ZhengH.FridkinM.YoudimM. B. H. (2010a). Site-activated chelators derived from anti-parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease. Neurochem. Res.35, 2117–2123. 10.1007/s11064-010-0293-1
80
ZhengH.GalS.WeinerL. M.Bar-AmO.WarshawskyA.FridkinM.et al. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem.95, 68–78. 10.1111/j.1471-4159.2005.03340.x
81
ZhengH.YoudimM. B. H.FridkinM. (2010b). Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem. Biol.5, 603–610. 10.1021/cb900264w
Summary
Keywords
multi-target drugs, Alzheimer's Disease, in silico, datamining, rational drug design, repurposing
Citation
Hughes RE, Nikolic K and Ramsay RR (2016) One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. Front. Neurosci. 10:177. doi: 10.3389/fnins.2016.00177
Received
22 February 2016
Accepted
06 April 2016
Published
25 April 2016
Volume
10 - 2016
Edited by
Eero Vasar, University of Tartu, Estonia
Reviewed by
John J. Wagner, University of Georgia, USA; Min-Yu Sun, Washington University in St. Louis, USA; Elizabeth Yuriev, Monash University, Australia
Updates
Copyright
© 2016 Hughes, Nikolic and Ramsay.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rona R. Ramsay rrr@st-andrews.ac.uk
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.